🇺🇸 FDA
Patent

US 8268851

Compositions and methods for inhibition of the JAK pathway

granted A61PA61P27/02A61P27/06

Quick answer

US patent 8268851 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P27/02, A61P27/06, A61P27/14, A61P37/06